AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the recipient of unusually large options trading on Monday. Investors bought 7,601 put options on the company. This represents an increase of 1,385% compared to the typical volume of 512 put options.

A number of brokerages have commented on AVEO. Piper Jaffray Companies set a $2.00 price objective on AVEO Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. FBR & Co restated a “buy” rating and set a $3.00 price objective on shares of AVEO Pharmaceuticals in a research report on Friday, June 30th. ValuEngine upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 24th. BidaskClub upgraded AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Finally, Zacks Investment Research upgraded AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $3.08.

Several large investors have recently made changes to their positions in the company. RA Capital Management LLC acquired a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at about $18,727,000. NEA Management Company LLC increased its stake in shares of AVEO Pharmaceuticals by 57.9% in the first quarter. NEA Management Company LLC now owns 16,362,694 shares of the biopharmaceutical company’s stock valued at $9,654,000 after buying an additional 6,000,000 shares during the period. Sphera Funds Management LTD. acquired a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at about $1,711,000. Perceptive Advisors LLC increased its stake in shares of AVEO Pharmaceuticals by 64.3% in the first quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock valued at $3,014,000 after buying an additional 2,000,000 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of AVEO Pharmaceuticals by 48.6% in the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the period. Institutional investors own 51.03% of the company’s stock.

Shares of AVEO Pharmaceuticals (AVEO) opened at 3.09 on Thursday. The firm’s 50-day moving average price is $2.61 and its 200-day moving average price is $1.20. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.30. The firm’s market capitalization is $341.02 million.

ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals Sees Unusually Large Options Volume (AVEO)” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/17/aveo-pharmaceuticals-sees-unusually-large-options-volume-aveo.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.